- Adjuvant treatment in stage III colorectal cancer:
- PO 1,250mg/m2 BD *2/52, then 1-week rest period given as 3-week cycles for a total of 8 cycles (24 weeks)
- First-line monotherapy for metastatic colorectal carcinoma:
- PO 1,250mg/m2 BD *2/52, then 1-week rest period; given as 3-week cycles
- PO 1,250mg/m2 BD *2/52, then 1-week rest period; given as 3-week cycles
- Refractory/relapsed metastatic breast cancer:
- Monotherapy in disease resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen:
- PO 1250mg/m2 BD *2/52 followed by 1-week rest period; given as 3-week cycles
- PO 1250mg/m2 BD *2/52 followed by 1-week rest period; given as 3-week cycles
- Monotherapy in disease resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen:
-
- Combination with docetaxel after failure of prior anthracycline-containing chemotherapy:
- PO 1250mg/m2 BD on days 1-14 plus docetaxel 75mg/m2 1hr IV infusion on Day 1 of a 3-week cycle
- PO 1250mg/m2 BD on days 1-14 plus docetaxel 75mg/m2 1hr IV infusion on Day 1 of a 3-week cycle
- Combination with docetaxel after failure of prior anthracycline-containing chemotherapy:
-
- Combination with lapatinib (Off-label):
- PO 1000mg/m2/dose BD on days 1-14 of 21-day cycle
- For patients with HER2-overexpressing disease who have received prior treatment including anthracycline, taxane and trastuzumab
- Combination with lapatinib (Off-label):
-
- Combination with neratinib (Off-label):
- PO 750mg/m2/dose BD on days 1-14 of 21-day cycle
- For patients with HER2-overexpressing disease who have received 2 or more anti-HER2 based regimens
- Combination with neratinib (Off-label):
Tablet:
- 150mg
- 500mg
To be taken after meals
Fluoropyrimidine carbamate antimetabolite
It is a prodrug of 5’-deoxy-5-fluorouridine (F’-DFCR) which is converted to 5-fluorouracil (5-FU)
Tumor cells and normal cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP)
- Hand-foot syndrome
- Diarrhea
- Nausea & vomiting
- Anemia
- Stomatitis
- Abdominal pain
- Hyperbilirubinemia
- Fatigue
- Dermatitis
- Constipation
- Fever
- Lymphopenia
- Neutropenia
- Anorexia
- Headache
- Dizziness
- Edema
- Ocular irritation
- Asthenia
- Lethargy
- Alopecia
- Dyspnea
- Dyspepsia
- Pain
- Rash
- Dysgeusia
- Peripheral neuropathy
- Insomnia
- Dehydration
- Conjunctivitis
- Arthralgia
- Venous thrombosis
- Cough
- Skin discoloration
- Thrombocytopenia
- Epistaxis
- Chest pain
- GI hemorrhage
- Ileus
- Hypersensitivity to class/compound
- Hypersensitivity to fluorouracil
- Dihydropyrimidine dehydrogenase deficiency
- Pregnancy 1st trimester
- Breastfeeding during treatment and for 2 week after discontinuing
- Baseline ANC <1500
- Baseline Plt <100,000
- CrCl <30
- Live bacterial vaccines
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Bdocin | 500mg | Tablet | 120s | BDR Pharma | Ripple Pharma |
| Capecitabine Sandoz | 150mg | Tablet | 60’s | Sandoz GMBH | Novartis Kenya |
| Capecitabine Sandoz | 500mg | Tablet | 120’s | Sandoz GMBH | Novartis Kenya |
| Capemax | 150mg | Tablet | 30’s | Intas Pharma | Accord Healthcare |
| Capemax | 500mg | Tablet | 30’s | Intas Pharma | Accord Healthcare |
| Capetero | 500mg | Tablet | 10’s | Hetero Labs | Unisel Ltd |
| Capxcel | 500mg | Tablet | 10’s | PSM Pharma | PSM Pharma |
| Emcap | 500mg | Tablet | 120’s | MSN Labs | MSN Labs |
| Glocapx | 500mg | Tablet | 120’s | Globela Pharma | Globela Pharma |
| Naprocap | 500mg | Tablet | 10’s | Miracalus | Ripple Pharma |
| Xeloda | 150mg | Tablet | 60’s | F. Hoffman-La Roche | Roche Kenya |
| Xeloda | 500mg | Tablet | 120’s | F. Hoffman-La Roche | Roche Kenya |